Enzymotec Ltd. Granted a New US Patent for Vayacog(R) in Pre-Dementia
28 October 2015 - 11:30PM
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid based nutritional
ingredients and medical foods, announced today it was granted a new
patent by the United States Patent and Trademark Office for
Vayacog®, a proprietary prescription medical food for the dietary
management of lipid imbalances associated with early memory
impairment.
The granted patent covers a method of improving a condition in
the elderly suffering from specified cognitive disorders using
Vayacog®. The disorders covered by the patent include
pre-Alzheimer's disease and pre-dementia syndrome.
Vayacog® is a unique lipid composition essential for the
management of key biochemical modifications underlying losses in
brain function. There is currently a 24-month, multi-center
clinical trial being conducted to evaluate its long-term efficacy
in patients with Mild Cognitive Impairment ("MCI"). Vayacog® has
been shown to be safe and efficacious in earlier clinical trials in
non-demented subjects with memory complaints.
Rob Crim, President of VAYA Pharma, a division of Enzymotec,
commented, "We continue to strengthen our intellectual property
portfolio with the grant of this patent. While we work toward
statistical data to make Vayacog® a standard protocol for the
management of MCI, this new patent reinforces our competitive
advantage. With the support of our IP, we remain focused on trial
data to illustrate the effectiveness of our marketed products."
About VAYA Pharma
VAYA Pharma is a specialty pharmaceutical division of Enzymotec
Ltd. dedicated to the discovery, development, manufacture and
marketing of innovative proprietary clinically tested lipid-based
compositions familiar to the human body for addressing disorders
that are impacted by lipid imbalances. VAYA Pharma's medical food
portfolio addresses three therapeutic segments: ADHD (Vayarin®),
Early Memory Impairment (Vayacog®) and Hypertriglyceridemia
(Vayarol®). VAYA Pharma products are available in the US only by
prescription under the supervision of a physician. For more
information, visit www.vayapharma.com.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-active lipid ingredients, as well as final
products, based on sophisticated processes and technologies. For
more information, visit www.enzymotec.com.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences include the following risks: A high proportion of
the sales of the InFat product is sold to end users in China and to
a single company; Growth in the Chinese economy has moderated and
this slowdown and related volatility could adversely impact demand
in China for our products; The demand for products based on Omega-3
and in particular, premium products, such as krill oil, has
declined and may continue to decline following a significant
increase in manufacturing capacity by manufacturers of these
products, resulting in intense competition and price pressure; Our
offering of products as "medical foods" in the United States may be
challenged by regulatory authorities; We rely on our Swedish joint
venture partner to manufacture InFat and certain matters related to
the joint venture are the subject of disagreement in an arbitration
proceeding; We are subject to a degree of customer concentration
and our customers do not enter into long-term purchase commitments
with us; We depend on third parties to obtain raw materials, in
particular krill, necessary for the production of our products; We
are dependent on a single facility that houses the majority of our
operations; We may have to pay royalties with respect to sales of
our krill oil products in the United States or Australia and any
infringement of intellectual property of others could also require
us to pay royalties; Potential future acquisitions of companies or
technologies may distract our management, may disrupt our business
and may not yield the returns expected; We anticipate that the
markets in which we participate will become more competitive and we
may be unable to compete effectively; We may not be able to
successfully expand our production or processing capabilities; Our
ability to obtain krill may be affected by conservation regulation
or initiatives; Our product development cycle is lengthy and
uncertain, and our development or commercialization efforts for our
products may be unsuccessful; and other factors discussed under the
heading "Risk Factors" in the Company's Form 20-F filed with the
Securities and Exchange Commission on March 2, 2015.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: The Ruth Group
Tram Bui / Lee Roth
646-536-7035 / 7012
tbui@theruthgroup.com
lroth@theruthgroup.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024